Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clozapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 10/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 9/20 | 1.00 |
| ▸ | DRD4 | P21917 | 7/20 | 1.00 |
| ▸ | DRD1 | P21728 | 4/20 | 1.00 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clozapine SCHEMBL8397 | 1.00 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL20876213 | 1.00 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL29360001 | 1.00 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL5501558 | 1.00 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL29590817 | 1.00 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL28700741 | 0.99 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL28648626 | 0.99 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL29180214 | 0.99 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL140458 | 0.99 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL29041024 | 0.99 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024249914-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DYSTONIA | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | WO | claimed |
| CN-113286777-B | Compounds, compositions and methods for modulating iron death and treating excitotoxic disorders | 纽约市哥伦比亚大学理事会 | 2024-10-29 | — | — | CN | claimed |
| EP-4688561-A1 | HYDRAULIC ACTUATION SYSTEM WITH INTEGRATED HEATER AND AIRCRAFT COMPRISING SAME | Safran Landing Systems (FR) | 2026-02-11 | — | — | EP | disclosed |
| EP-4661017-A1 | MENTAL ILLNESS DIAGNOSIS AND DRUG RECOMMENDATION METHOD | Samsung Life Public Welfare Foundation (KR) | 2025-12-10 | — | — | EP | disclosed |
| US-20250345433-A1 | Drug For Treating Disorders Of An Organ Or Tissue Function And Diseases Accompanied By Such Disorders, And The Method For Obtaining It | Epshtein, Oleg Iliich (RU) | 2025-11-13 | — | — | US | disclosed |
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4562001-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | Nura Bio, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2025090514-A1 | COVALENT SARM1 INHIBITORS | NURA BIO, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025015222-A2 | PHARMACEUTICAL COMPOSITIONS | REBEL MEDICINE INC (US) | 2025-01-16 | — | — | WO | disclosed |
| US-20240424135-A1 | Compositions For and Methods of Improving Viral Vectors | DUKE UNIVERSITY | 2024-12-26 | — | — | US | disclosed |
| WO-2024249914-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DYSTONIA | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | WO | disclosed |
| EP-4185862-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A DYSTONIA | Duke University (US) | 2023-05-31 | — | — | EP | disclosed |
| US-11629136-B1 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-20230105696-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2023009663-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023288247-A1 | COMPOSITIONS FOR AND METHODS OF IMPROVING VIRAL VECTORS | DUKE UNIVERSITY (US) | 2023-01-19 | — | — | WO | disclosed |
| US-11490856-B2 | Method and a system for analyzing neuropharmacology of a drug | CITY UNIVERSITY OF HONG KONG (HK) | 2022-11-08 | — | — | US | disclosed |
| WO-2022060812-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220081417-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2022-03-17 | — | — | US | disclosed |
| WO-2022056475-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A DYSTONIA | DUKE UNIVERSITY (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | DRD2 4496/4885HTR2A 3472/4885CHRM1 2416/4885 |
| US-11629136-B1 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | DRD2 4304/4885HTR2A 3301/4885CHRM1 2446/4885 |
| US-20220081417-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | SARM1, SARNP, ADRM1 | DRD2 4505/4885HTR2A 3572/4885CHRM1 2454/4885 |
| US-20230105696-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | SARM1, SARNP, ADRM1 | DRD2 4304/4885HTR2A 3301/4885CHRM1 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.